Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors.

Cancer Med · 2017 · PMC5504331 · PMID 28547856

Europe PMC DOI

hedged sentence

0.7401

closest p · 14.8× alpha

0.7401

boldest claim

The sentences

showed a trendP = 0.7401not close (p > 0.1)

The Kaplan–Meier analysis showed a trend toward better OS ( P = 0.7401) in patients that experienced neither dose reduction nor dose delay (median OS not reached), followed by patients that experienced only dose delay (median OS not reached), than patients with only dose reduction (median OS = 124 months) and finally patients that experienced both dose reduction and dose delay (median OS = 92 months).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.